Evidence map›Paper›PMID 41422222›Full record

ArticleBMC rheumatology2025

Sjögren's Hands-On Practice Exchange (SHAPE): a qualitative, expert opinion project in Sjögren's disease clinical practice.

Emily Gregg, Charlotte Graham, Deborah Watkins, Viviam Canon Garcia, Rachael McCool

Abstract read
In one paragraph

Article in BMC rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Emily GreggYork Health Economics Consortium, Enterprise House, University of York, Heslington, YO10 5NQ, UK. emily.gregg@york.ac.uk.ORCID http://orcid.org/0009-0003-2969-793X
Charlotte GrahamYork Health Economics Consortium, Enterprise House, University of York, Heslington, YO10 5NQ, UK.ORCID http://orcid.org/0009-0001-6599-7425
Deborah WatkinsYork Health Economics Consortium, Enterprise House, University of York, Heslington, YO10 5NQ, UK.ORCID http://orcid.org/0009-0005-0849-0299
Viviam Canon GarciaNovartis Pharma AG, Basel, CH-4056, Switzerland.ORCID http://orcid.org/0009-0008-6628-9595
Rachael McCoolYork Health Economics Consortium, Enterprise House, University of York, Heslington, YO10 5NQ, UK.ORCID http://orcid.org/0000-0001-6690-9952

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSjögren’s disease (SjD) is a multifaceted, systemic autoimmune disease with substantial clinical heterogeneity. The objective of this study was to conduct a qualitative expert opinion exercise to explore how SjD is assessed, evaluated and managed in international clinical practice.

methodsA qualitative research design was used to elicit the expert opinion of 8 clinicians. Two researchers interviewed each clinician individually. The results of the interviews were synthesised using thematic analysis, and draft definitions of key terms were prepared. A group workshop was held to discuss/validate the interview results and refine the working definitions.

resultsThe clinicians had extensive experience in managing SjD from different countries. Seven topics emerged as major themes: disease classification, disease activity, relevant subpopulations, disease severity, disease progression, disease remission, and unmet needs. For 4 of these topics, there was no consensus – particularly regarding definitions that could be used in a clinical setting. The terms “systemic involvement” and “extra-glandular symptoms” have similar meanings but lack consistent application between clinicians. There was a lack of consensus on what “severity” refers to – whether it is severity of disease damage, the nature of disease manifestations, the potential for irreversible damage, or level of symptoms. There were also conflicting opinions regarding whether patient perspectives should be incorporated in key definitions.

conclusionThere is currently a lack of standard definitions specifically for daily practice, which may contribute to high variability in clinical assessment and management. The definitions proposed in this study represent initial working concepts and are intended as a first step to promote further discussion among SjD experts to facilitate a more unified routine evaluation of patients. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Expert opinionQualitative researchRheumatic diseaseSjögren’s disease

Identifiers

PMID41422222
PMCPMC12781536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.